The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Tube repairs should be nearly completed by now.
Cement shortly after that.
Hopefully the high pressure and natural fisher will result in higher flow volume.
Short term the pressure event was bad long-term it could be very good.
The removal and repair of the tubing must be nearly completed.
Cement shortly.
Very hopeful that this high pressure naturally fisher will result in some very high flow rates.
Short term this pressure event may have been bad but long term it could be very good
The SP has fallen because Modi 1 has not lived up to some PI's expectations.
After Trish blog some were expecting all patients to have tumour reduction after one dose.
The ground breaking results will come with the trails incorporating CPI.
It could start with SCIB 1 but Modi 1 will follow shortly after.
That's when you will see the SP reflect the great science Scancell has
"Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company"
Is this the long awated data so we can do the BioNTech deal
Very bullish talk on time lines to phase 3 and to product launch.
This must indicate that trial results to date are very positive.
I would also suggest that they must be in talks with someone to be that positive